https://www.foxbusiness.com/markets/fda-approves-odomza-from-novartis-for-increasingly-common-skin-cancer-basal-cell-carcinoma
FDA approves Odomza from Novartis for increasingly common skin cancer, basal cell carcinoma | Fox...
A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval.